Navigation Links
Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients

WALTHAM, Mass., April 14, 2011 /PRNewswire/ -- Proteon Therapeutics, Inc. has initiated enrollment in a Phase 2 clinical study of its lead product, PRT-201, in chronic kidney disease (CKD) patients undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis. This study follows successful completion of a 66-patient, double-blind, placebo-controlled Phase 1/2 study of PRT-201 in AVF patients that completed enrollment in July 2010.

"Our lead product, PRT-201, represents a highly innovative approach to addressing the significant medical challenges associated with vascular access in CKD patients, and we are very excited about the potential for PRT-201 to dramatically improve care for dialysis patients," said Timothy P. Noyes, President and CEO of Proteon.  

The results of this Phase 2 study will be provided to Novartis under an agreement entered into in 2009, whereby Novartis was granted an exclusive option to acquire Proteon following the completion of a Phase 2 clinical study of PRT-201. Including the initial acquisition payment plus potential regulatory milestone payments, the acquisition deal with Novartis could exceed $550 million.

About PRT-201

PRT-201 is an investigational recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) and arteriovenous graft (AVG) outcomes in patients requiring chronic hemodialysis. PRT-201 has been shown in certain preclinical settings to reduce neointimal hyperplasia formation, and to cause dilation of segments of arteries and veins following topical intraoperative application. These effects may decrease the number of interventions necessary to maintain AVF and AVG patency. Improved patency may lead to fewer corrective surgical procedures, fewer hospitalizations, lower costs and less suffering for dialysis patients. The development program to investigate PRT-201 for improving vascular access has been designated a fast track program by the FDA.  

About Proteon Therapeutics

Proteon Therapeutics, Inc. is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is headquartered in Waltham, Mass., and has research facilities in Kansas City, Mo. For additional information, please visit

SOURCE Proteon Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
2. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
3. Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
4. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
5. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
7. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
8. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
9. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
10. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
11. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
Post Your Comments:
(Date:11/28/2015)... ... November 28, 2015 , ... • Jeon Jin Bio Corp, a Korean ... control solutions , Bird Free, an oil-based, ... all sensory modalities including visual, smell, taste and touch, enabling safe, effective avian control ...
(Date:11/26/2015)... England , November 26, 2015 ... an innovative medical device company specializing in imaging technologies, announced ... the European Commission as part of the Horizon 2020 European ... to carry out a large-scale clinical trial in breast cancer. ...      (Logo: , --> ...
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... market report published by Transparency Market Research "Home Security Solutions ... and Forecast 2015 - 2022", the global home security solutions ... bn by 2022. The market is estimated to expand ... from 2015 to 2022. Rising security needs among customers ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
Breaking Biology News(10 mins):